MULTISTRATEGY: tirofiban and sirolimus in primary PCI

Lindsay, Alistair C.; Qureshi, Katie
August 2008
Heart;Aug2008, Vol. 94 Issue 8, p1102
Academic Journal
The article offers information on the use of MULTISTRATEGY trial in comparing the efficacy of tirofiban and sirolimus in treating patients undergoing primary percutaneous coronary intervention (PCI). It discusses a study of patients with ST-segment elevation myocardial infarction (STEMI) across medical centers in Italy, Spain and Argentina.


Related Articles

  • Drug-Eluting Stents in Acute Myocardial Infarction. Van de Werf, Frans // New England Journal of Medicine;9/14/2006, Vol. 355 Issue 11, p1169 

    The author suggests that larger, more conclusive clinical trials are necessary before routine implantation of drug-eluting stents can be recommended for all patients undergoing primary percutaneous coronary interventions. He cites two articles in this issue, "Sirolimus-Eluting versus Uncoated...

  • Severity of MI dependent on time of day.  // Cardiology Today;Jan2012, Vol. 15 Issue 1, p36 

    The article discusses a study which found that the size of a myocardial infarction and subsequent left ventricular function can be affected by the time-of-day onset.

  • Association of GRACE Risk Score with Angiographic Severity of Coronary Artery Disease in patients with ST Elevation Myocardial Infarction. Saha, Tapash; Khalequzzaman, Md.; Kader Akanda, Md. Abdul; Saha, Simu; Tushar, Asif Zaman; Ahmed, Rashid; Saha, Gouranga Kumar; Ullah, Mohammad // Cardiovascular Journal;2015, Vol. 8 Issue 1, p30 

    Background: Clinical guidelines recommend that optimal management of acute coronary syndrome should include patient risk stratification. Predicting the anatomical extension of coronary artery disease is also potentially useful for clinical decision. The objective of our study is to determine...

  • Current management of patients with ST elevation myocardial infarction in Metropolitan Beijing, China. Shou -Yan Zhang; Da -Yi Hu; Yi -Hong Sun; Jin- Gang Yang // Clinical & Investigative Medicine;Aug2008, Vol. 31 Issue 4, pE189 

    Purpose: To assess clinical practices and in-hospital outcomes of patients with ST elevation myocardial infarction (STEMI) in Beijing, China. Methods: This study was a prospective multicentre registry study in Metropolitan Beijing, China. Demographics, delay time, management strategy and...

  • Clinical digest. Morning heart attacks are more severe than those later in the day.  // Nursing Standard;6/15/2011, Vol. 25 Issue 41, p17 

    The article reports on research which was published in a 2011 edition of the periodical "Heart" and found that heart attacks which occur in patients in the morning are usually more severe than those which occur later in the day.

  • Research Briefs - Estimates of MI risk.  // GP: General Practitioner;3/25/2011, p10 

    The article focuses on the research report according to which a sensitive troponin test can be used for detecting an coronary syndrome Myocardial infarction (MI) risk in the patients in the Great Britain.

  • Testosterone gels safer than injections.  // Reactions Weekly;May2015, Vol. 1553 Issue 1, p13 

    The article focuses on a study about men being treated with testosterone injections, which noted to have higher risks of acute cardiovascular events such as myocardial infarction and unstable angina pectoris or stroke.

  • Sirolimus-Eluting versus Uncoated Stents in Acute Myocardial Infarction. Spaulding, Christian; Henry, Patrick; Teiger, Emmanuel; Beatt, Kevin; Bramucci, Ezio; CarriĆ©, Didier; Slama, Michel S.; Merkely, Bela; Erglis, Andrejs; Margheri, Massimo; Varenne, Olivier; Cebrian, Ana; Stoll, Hans-Peter; Snead, David B.; Bode, Christoph // New England Journal of Medicine;9/14/2006, Vol. 355 Issue 11, p1093 

    Background: Sirolimus-eluting stents reduce rates of restenosis and reintervention, as compared with uncoated stents. Data are limited regarding the safety and efficacy of such stents in primary percutaneous coronary intervention (PCI) for acute myocardial infarction with ST-segment elevation....

  • ACCOAST: Prasugrel pretreatment increases major bleeding, does not benefit ischemic events. Ellis, Brian; Kalvaitis, Katie // Cardiology Today;Oct2013, Vol. 15 Issue 10, p21 

    The article discusses the results of the A Comparison of Prasugrel at Percutaneous Coronary Intervention (PCI) or Time of Diagnosis of Non-ST Elevation Myocardial Infarction (ACCOAST) study which show that prasugrel pretreatment increases major bleeding and does not benefit ischemic events.


Read the Article


Sign out of this library

Other Topics